L-Arginine HCl (L-Arg)

製品コードS3174 バッチS317402

印刷

化学情報

Chemical Structure Synonyms (S)-(+)-Arginine hydrochloride Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C6H14N4O2.HCl
分子量 210.66 CAS No. 1119-34-2
Solubility (25°C)* 体外 Water 42 mg/mL (199.37 mM)
DMSO Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 L-Arginine(L-arg,(S)-(+)-Arginine hydrochloride) is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis.
in vitro

L-Arginine (0.3 mM, 30 minutes) supplementation do not induce any significant increases in the peak NO concentration at low level of native LDL. However, at native LDL concentrations from 60-130 mg cholesterol/dL, NO concentration is 2 times higher than before L-Arginine treatment in bovine aortic endothelial cells. L-Arginine (0.3 mM, 30 minutes) pretreatment results in a significant increase of NO production in n-LDL–treated cells as well as in oxidized -LDL–treated cells in bovine aortic endothelial cells. L-Arginine (0.3 mM, 30 minutes) does not increase O2- concentration at low nativeLDL concentrations but reduce O2- production by 50% when incubate with n-LDL at concentrations >40 mg cholesterol/dL in bovine aortic endothelial cells. L-Arginine (0.3 mM, 30 minutes) pretreatment completely abolishes O2- production at every oxidized LDL dosage in bovine aortic endothelial cells. [1]
in vivo

L-Arginine (4 mg/kg/min for 1 hour) treatment decreases superoxide generation by cNOS while increasing NO accumulation in rabbit limb during ischemia/reperfusion. L-Arginine (4 mg/kg/min for 1 hour) prevents microvessel constriction in the reperfused muscle despite reduced but still apparent interstitial edema in rabbit limb. L-Arginine (4 mg/kg/min for 1 hour) treatment results in a significant reduction of muscular reperfusion edema in rabbit limb. [2] L-Arginine (0.1 g/kg, oral) supplementation significantly reduces pulmonary artery systolic pressure by a mean of 15.2% after 5 days of therapy in patients with sickle cell disease. Both L-Arginine and ornithine concentrations increased significantly after 5 days of oral L-Arginine (0.1 g/kg) supplementation in patients with sickle cell disease. [3] L-Arginine is associated with a decrease in cardiac index while stroke index is maintained in patients with severe sepsis. Resolution of shock at 72 hours is achieved by 40% and 24% of the patients in the L-Arginine and placebo cohorts, respectively. [4] L-Arginine (450 mg/kg during a 15-minute period) amplifies and sustains the hyperemia (38%) and increases absolute brain blood flow after eNOS upregulation by chronic simvastatin treatment (2 mg/kg subcutaneously, daily for 14 days) in SV-129 mice. [5]

プロトコル(参考用のみ)

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

P4HA1 as an unfavorable prognostic marker promotes cell migration and invasion of glioblastoma via inducing EMT process under hypoxia microenvironment [ Am J Cancer Res, 2021, 11(2):590-617] PubMed: 33575089
S100A9 gene silencing inhibits the release of pro‐inflammatory cytokines by blocking the IL‐17 signalling pathway in mice with acute pancreatitis [Dong‐Mei Wu, et al. J Cell Mol Med, 2018, 10.1111/jcmm.13532]
S100A9 gene silencing inhibits the release of pro-inflammatory cytokines by blocking the IL-17 signalling pathway in mice with acute pancreatitis. [ J Cell Mol Med, 2018, 22(4):2378-2389] PubMed: 29441717

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。